Govt Support Bolsters Pharmicell’s Stem Cell Therapy Plans
This article was originally published in PharmAsia News
Executive Summary
Pharmicell is to kick off the development of a stem cell-based therapy for chronic kidney disease and a gene therapy for liver cancer with support from the South Korean government, which is nurturing the development of both sectors as part of a national strategic plan.
You may also be interested in...
Pharmicell Eyes US After Promising Cirrhosis Cell Therapy Results
South Korea's Pharmicell is taking steady steps towards commercializing a stem cell therapy for alcoholic liver cirrhosis, an area with outstanding needs, following a successful Phase II domestic trial that lays the ground for a Phase III program and the start of US clinical development.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.